Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Brandt

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Therapeutic Innovation & Regulatory Science|November 18, 2022
Regulatory Considerations Toward Orphan Drug Designation and Orphan Drug Exclusivity in the United States and European Union: Structural Similarity, Clinical Superiority/Significant Benefit, and Case StudiesScott W Roberts, Tara Laura Brandt Elvang, Laila Syed, et al.
Therapeutic Innovation & Regulatory Science|December 6, 2022
Correction: Regulatory Considerations Toward Orphan Drug Designation and Orphan Drug Exclusivity in the United States and European Union: Structural Similarity, Clinical Superiority/Significant Benefit, and Case StudiesScott W Roberts, Tara Laura Brandt Elvang, Laila Syed, et al.
JAMA Psychiatry|October 4, 2023
Individual-Level Risk Prediction of Return to Use During Opioid Use Disorder TreatmentSean X Luo, Daniel J Feaster, Ying Liu, et al.
Human Resources for Health|September 3, 2020
Implementation and evaluation of a Project ECHO telementoring program for the Namibian HIV workforceLeonard Bikinesi, Gillian O'Bryan, Clay Roscoe, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Therapeutic Innovation & Regulatory Science|November 18, 2022
Regulatory Considerations Toward Orphan Drug Designation and Orphan Drug Exclusivity in the United States and European Union: Structural Similarity, Clinical Superiority/Significant Benefit, and Case StudiesScott W Roberts, Tara Laura Brandt Elvang, Laila Syed, et al.
Therapeutic Innovation & Regulatory Science|December 6, 2022
Correction: Regulatory Considerations Toward Orphan Drug Designation and Orphan Drug Exclusivity in the United States and European Union: Structural Similarity, Clinical Superiority/Significant Benefit, and Case StudiesScott W Roberts, Tara Laura Brandt Elvang, Laila Syed, et al.
JAMA Psychiatry|October 4, 2023
Individual-Level Risk Prediction of Return to Use During Opioid Use Disorder TreatmentSean X Luo, Daniel J Feaster, Ying Liu, et al.
Human Resources for Health|September 3, 2020
Implementation and evaluation of a Project ECHO telementoring program for the Namibian HIV workforceLeonard Bikinesi, Gillian O'Bryan, Clay Roscoe, et al.
Pageof 6